Prognostic role of tissue plasminogen activator in coronary artery disease with or without aortic valve sclerosis

Aims We sought to investigate the relationship between circulating tissue plasminogen activator (t‐PA) level and long‐term outcomes in stable coronary artery disease patients with or without aortic valve sclerosis (AVSc). Methods and results Serum levels of t‐PA were determined in 347 consecutive st...

Full description

Saved in:
Bibliographic Details
Published in:ESC Heart Failure 2023-08, Vol.10 (4), p.2541-2549
Main Authors: Lin, Bowen, Shen, Ying, Zhang, Pengfei, Shen, Yunli, Gu, Yuying, He, Xiaoyan, Li, Jimin, Yang, Ke, Shen, Weifeng, Zhang, Qi, Xin, Yuanfeng, Liu, Yehong
Format: Article
Language:English
Subjects:
Aortic valve sclerosis
Bats
Body mass index
Cardiovascular disease
Coronary artery disease
Mortality
Original
Prognosis
Tissue plasminogen activator
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims We sought to investigate the relationship between circulating tissue plasminogen activator (t‐PA) level and long‐term outcomes in stable coronary artery disease patients with or without aortic valve sclerosis (AVSc). Methods and results Serum levels of t‐PA were determined in 347 consecutive stable angina patients with (n = 183) or without (n = 164) AVSc. Outcomes were prospectively recorded as planned clinic evaluations every 6 months up to 7 years. The primary endpoint was a composite of cardiovascular death and rehospitalization due to heart failure. The secondary endpoint included all‐cause mortality, cardiovascular death, and rehospitalization due to heart failure. Serum t‐PA was significantly higher in AVSc than in non‐AVSc patients (2131.22 pg/mL vs. 1495.85 pg/mL, P 1840.68 pg/mL) were more likely to meet the primary and secondary endpoints (all P 
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.14420